Verastem Oncology reported a GAAP net loss of $98.5 million, or $1.35 per share (basic and diluted), for the third quarter ended September 30, 2025, compared to a GAAP net loss of $24.0 million, or $0.60 per share, for the same period in 2024. The non-GAAP adjusted net loss for the quarter was $39.4 million, or $0.54 per share (diluted), versus $35.3 million, or $0.88 per share (diluted), in the third quarter of 2024. The company ended the quarter with $137.7 million in cash, cash equivalents, and investments, and expects its cash runway to extend into the second half of 2026 with current resources including product revenue and exercise of cash warrants. Verastem also provided recent business updates during the period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104228194) on November 04, 2025, and is solely responsible for the information contained therein.